Package 72865-144-60

{"route": ["ORAL"], "spl_id": "f26f80c3-6ad3-2c78-e053-2995a90a7783", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "upc": ["0372865144602"], "unii": ["2T8Q726O95", "4B9XT59T7S"], "rxcui": ["200082"], "spl_set_id": ["55520835-0f24-4e52-af8c-d65841ccaba7"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["XLCare Pharmaceuticals, Inc"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "60 TABLET, FILM COATED in 1 BOTTLE (72865-144-60)", "package_ndc": "72865-144-60", "marketing_start_date": "20200417"}], "brand_name": "LAMIVUDINE AND ZIDOVUDINE", "product_id": "72865-144_f26f80c3-6ad3-2c78-e053-2995a90a7783", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "product_ndc": "72865-144", "generic_name": "lamivudine and zidovudine", "labeler_name": "XLCare Pharmaceuticals, Inc", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "LAMIVUDINE AND ZIDOVUDINE", "active_ingredients": [{"name": "LAMIVUDINE", "strength": "150 mg/1"}, {"name": "ZIDOVUDINE", "strength": "300 mg/1"}], "application_number": "ANDA203259", "marketing_category": "ANDA", "marketing_start_date": "20200417", "listing_expiration_date": "20261231"}